Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody and Lenalidomide for EBV-HLH or CAEBV
NCT04084626Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and chronic active Epstein-Barr virus infection (CAEBV), sponsored by Beijing Friendship Hospital. Primary endpoint: Response rate at 6 months. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT04084626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084626.